VOTRIENT (pazopanib)

VOTRIENT (pazopanib)

SELF ADMINISTRATION - ORAL

Indications for Prior Authorization:

• Treatment of advanced renal cell carcinoma
• Advanced soft tissue sarcoma in patient who have received previous chemotherapy

The Following Conditions Do Not Meet the Criteria for Use as Established by the WHA P & T Committee:

• All non-FDA approved uses not listed in the approved indications

Dosing:

• 800 mg once daily without food
• 200 mg once daily for patient with moderate hepatic impairment
• Not recommend for patient with severe hepatic impairment

Warning:

• Severe and fatal hepatotoxicity was observed in clinical trial

Approval:

• Initial approval 6 weeks
• Renewal: 6 months